SIMR (Australia) Biotech

Shanghai, China· Est. 2014

SIMR Biotech is a clinical-stage biopharma company developing novel drugs for pain, inflammation, and CNS diseases through a patient-data-driven translational platform.

simrbio.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

SIMR Biotech is a clinical-stage biopharma company developing novel drugs for pain, inflammation, and CNS diseases through a patient-data-driven translational platform.

MetabolicInflammationCentral Nervous System

Technology Platform

A patient-data-driven translational research platform that utilizes clinical insights and specialized animal models to standardize and de-risk drug discovery and development.

Opportunities

Validating its translational platform through clinical success could attract partnership deals, particularly for its Lp-PLA2 inhibitor SR1375 in metabolic and inflammatory indications.

The large, unmet medical needs in chronic pain and DKD represent significant market opportunities.

Risk Factors

As a preclinical/clinical-stage biotech, it faces high clinical development risk and likely requires significant additional capital.

It operates in highly competitive therapeutic areas dominated by large pharmaceutical companies.

Competitive Landscape

Competes with numerous biopharma companies in pain, inflammation, and DKD (e.g., Vertex, Novo Nordisk, AstraZeneca). Its key claimed differentiation is its translational research strategy designed to improve the predictability and success rate of drug development.

More companies in China →